ÂÜÀòÂÒÂ×

Dr. Peter Tummino is Chief Scientific Officer of Nimbus. Prior to joining Nimbus, Peter was Vice President and Global Head of Lead Discovery in Discovery Sciences at Janssen, the Johnson & Johnson Pharmaceuticals Group. He led multiple aspects of discovery operations with teams located in Europe and both coasts of the U.S., working across all five therapeutic areas at Janssen. Prior to joining Janssen in 2014, Peter held multiple leadership roles at GlaxoSmithKline, including Head of Biology for the Cancer Epigenetics Discovery Performance Unit, where his team progressed first-in-class epigenetic agents into oncology clinical trials against multiple novel targets. Earlier in his GSK tenure, he contributed to the discovery and progression of multiple clinical candidates, including dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) which were approved for multiple oncology indications. During this time, he also co-led the novel target selection effort for GSK Oncology.

Peter received his Ph.D. from the Department of Biological Chemistry at the University of Michigan in 1992. Following completion of a postdoctoral fellowship at Warner-Lambert/Parke-Davis, he held positions of increasing responsibility at Warner-Lambert/Parke-Davis, AstraZeneca, and Millennium Pharmaceuticals. He has published 77 peer-reviewed journal articles with greater than 9000 citations.